September 22, 2014
Serum metabolites and metabolic pathways as novel prognostic markers and potential therapeutic targets for AML
HONOLULU, HI- University of Hawai'i Cancer Center's Dr. Wei Jia's collaborative article regarding acute myeloid leukemia (AML) has received the Cancer Center's September 2014 award as the "Publication of the Month." Dr. Wei Jia has acted as corresponding author to a report which has identified a panel of markers used in the identification of intermediate group prognosis in individuals with AML.
Acute myeloid leukemia (AML) is a group of hematological malignancies. AML patients can be divided into groups associated with variable health outcomes: favorable, intermediate, and unfavorable. While the favorable and unfavorable groups demonstrate clear prognoses, the outcome of the intermediate group is not as straightforward.
In collaboration with Dr. Sai-Juan Chen and Dr. Zhu Chen in Shanghai, China, Dr. Jia and his team used serum metabolic profiling as a measure, and subsequently determined that the profiles of AML patients were markedly different from those of healthy controls. Metabolite markers were differently expressed in serum which contributed to these different profiles.
Dr. Wei Jia explains: "In patients with AML, physicians can divide between favorable, intermediate, and unfavorable with associated prognostic outcomes. It would be valuable to those in the intermediate group to be able to use these molecular biomarkers to determine whether or not they face a poor prognosis. Based on the prognostic identification of intermediate group AML patients, a treatment plan can be better established."
Through this report, the authors support the use of serum metabolites and metabolic pathways as novel prognostic markers and potential therapeutic targets for AML. By incorporating these markers, intermediate group prognoses can be determined, and ultimately a treatment plan can be better established for low-survival rate patients. The study: "A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value" is published in the September 4, 2014 edition of Blood. http://www.ncbi.nlm.nih.gov/pubmed/25006128
August 19, 2014
UNIVERSITY OF HAWAII CANCER CENTER AND THE QUEEN'S MEDICAL CENTER LAUNCH NATIONAL CLINICAL DRUG TRIAL TO TEST NEW BLADDER CANCER DRUGNew drug could halt recurrence of bladder cancer, one of the most prevalent cancers in the U.S.
HONOLULU â€“ The University of Hawaii Cancer Center, in partnership with The Queen's Medical Center (Queen's) via the Hawaii Cancer Consortium, is launching a new national clinical drug trial looking at the effectiveness of a promising new drug against non-muscle invasive bladder cancer, the most common type of bladder cancer with very high recurrence rates.
Unlike other national drug trials based on the mainland, this clinical trial is based in Hawaii and is among the first to highlight Hawaii as a growing healthcare center and focal point between Asia and the U.S. in the fight against cancer. The project also highlights the specialty inpatient unit at Queen's where these early clinical trials can be safely performed.
"The medical community does not yet have an effective means of preventing bladder cancer from recurring with currently available treatments," said Dr. Charles Rosser, a UH Cancer Center urologist and principal investigator of the trial. "Finding an effective treatment would go a long way towards preventing more people from suffering from this disease."
The trial will examine the efficacy of ALT-803, a drug created by Florida-based Altor BioScience Corp., a developer of cancer immunotherapies. In early studies, the drug showed strong potential to stimulate the body's immune system and create a protective and long-lasting effect against tumors. Altor BioScience has received a $1.2 million Small Business Innovation Research grant from the National Cancer Institute to test ALT-803 against non-muscle invasive bladder cancer for this Phase I/II trial.
Patients will be treated at Queen's, in a 6-bed unit located on the Oncology floor. Queen's has the only in-patient Clinical Trials Unit focusing on translational research in Hawaii â€“ in particular, Phase I/II trials. "This is the beginning of many future endeavors partnering with the UH Cancer Center to bring new cancer treatment/trials to Hawaii," said Darlena Chadwick, Vice President of Patient Care at Queen's. "Thanks to the establishment of the Hawaii Cancer Consortium, we are able to attract and recruit innovative researchers like Dr. Rosser, who will engage and work with our local physicians in order to bring their new treatments to the people of Hawaii."
Developing novel effective treatments for bladder cancer is important because bladder cancer has a high rate of recurrence, making it one of the most expensive cancers to treat on a per patient basis. Up to 70 percent of patients with non-muscle invasive bladder cancer may develop cancer recurrence, making it one of the most prevalent cancers in the U.S. The National Cancer Institute estimates nearly 74,700 new cases in the U.S. will be diagnosed in 2014, and nearly 15,600 people will die from it. More than half a million people in the U.S. are bladder cancer survivors.
About The UH Cancer Center
The UH Cancer Center is one of 68 research institutions designated by the National Cancer Institute. Affiliated with the University of Hawai`i at Manoa, the center is dedicated to eliminating cancer through research, education, and improved patient care. Learn more at www.uhcancercenter.org. Like us on Facebook at www.facebook.com/UHCancerCenter. Follow us on Twitter @UHCancerCenter.
About The Queen's Medical Center
The Queen's Medical Center, a 501 (c) (3) non-profit corporation established in 1859 by Queen Emma and King Kamehameha IV, is an acute care medical facility accredited by The Joint Commission. The facility is licensed for 505 acute beds and 28 sub-acute beds and serves as the major tertiary and quaternary referral center for cancer, cardiovascular disease, neuroscience, orthopaedics, surgery, emergency medicine and behavioral health medicine. It is the state's designated trauma center verified as Level 2 by the American College of Surgeons. It has the only organ transplantation program in Hawaii. Queen's is a major teaching hospital, serving as a clinical training site for the residency programs sponsored by the John A. Burns School of Medicine at the University of Hawaii. Queen's is the only hospital in Hawaii to achieve MagnetÂ® status â€“ the highest institutional honor for hospital excellence â€“ from the American Nurses Credentialing Center. The Queen's Medical Center has over 4,500 employees and over 1,200 physicians on its Medical Staff.
About Altor BioScience
Altor is a privately held biotechnology company developing immunotherapies for treating cancer, viral infection, and inflammatory diseases based on its proprietary IL-15, T cell receptor and Tissue Factor antagonist platform technologies. Altor currently has four Phase I and two Phase II trials underway for its product candidates against cancer. For more information, visit www.altorbioscience.com.
September 3, 2014
Support cancer research with your Foodland Give Aloha donation this month
Throughout September, Foodland is providing customers an opportunity to make a donation to the UH Cancer Center through its annual Give Aloha Program. Customers may make donations to the Cancer Center at any Foodland or Sack N Save store when checking out at the register.
Donors must present their Maika'i card at the time to ensure that their donation is matched by Foodland and partner Western Union Foundation. Donors need to identify the UH Cancer Center by name or its organization code number 77583 when designating the Cancer Center as the recipient of their donation.
The Friends of the University of Hawai'i Cancer Center sponsor the Cancer Center's participation in the Give Aloha Program. Donations made to the Cancer Center support cancer education programs for the public, start up funds for newly recruited researchers, and research initiatives for which no other source of funding is available.
July 16, 2014
"New donor-supported grants fund local cancer research"
The first ever Pilot Study Award was recently awarded to Dr. Brenda Hernandez and a team of UH Cancer Center researchers to study why women of Filipino ancestry are at higher risk for thyroid cancer. A second award was granted to Dr. Peter Hoffman to study whether inhibiting a specific enzyme can reduce inflammation in the intestine and the progression of inflammation-related colon cancer. In the picture at left, Dr. Brian Issel hands the award certificate to Dr. Hernandez; at right, Dr. Hoffman. Both awards were made possible by the generosity of community donors through the UH Foundation.